News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Conference News TCT 2022 HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza Todd Neale September 16, 2022
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Conference News ESC 2022 Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR L.A. McKeown August 27, 2022
News Conference News ESC 2022 No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE Shelley Wood August 26, 2022
News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Conference News EuroPCR 2022 MitraClip Helps for Atrial Functional MR: MITRA-TUNE Michael O'Riordan May 19, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News THT 2022 Probe Beyond Ejection Fraction to Understand and Manage HFpEF L.A. McKeown February 07, 2022
News Conference News THT 2022 Early Positive Signals From RELIEVE-HF Shift Discussion to Atrial Shunt Size Shelley Wood February 02, 2022
News Conference News THT 2022 REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF Shelley Wood February 01, 2022